People With Opioid Use Disorder Less Likely to Receive Palliative Care
By Elana Gotkine HealthDay Reporter
MONDAY, April 29, 2024 -- People with opioid use disorder (OUD) are less likely to receive palliative care during the last 90 days before death, according to a study published online April 29 in CMAJ, the journal of the Canadian Medical Association.
Jenny Lau, M.D., from the University Health Network in Toronto, and colleagues conducted a cohort study using health administrative databases to identify people who died between July 1, 2015, and Dec. 31, 2021, to compare palliative care provision during the last 90 days before death for decedents with and without OUD. Overall, 1.6 percent of 679,840 decedents had OUD.
The researchers found that people with OUD died at a younger age and were more likely to live in neighborhoods with high marginalization indices compared with people without OUD. People with OUD were less likely to receive palliative care at the end of their lives (adjusted relative risk, 0.84; 95 percent confidence interval, 0.82 to 0.76); after exclusion of those who died suddenly, this association did not persist (adjusted relative risk, 0.99; 95 percent confidence interval, 0.96 to 1.01). Regardless of cause of death, people with OUD were less likely to receive palliative care in clinics and their homes.
"People with OUD were less likely to receive palliative care despite accessing palliative care earlier, which may reflect their end-of-life illness trajectories and underlying structural vulnerability that may prompt them to receive palliative care primarily in acute care," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Inavolisib + Palbociclib-Fulvestrant Improves Survival in Advanced Breast Cancer
THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus palbociclib-fulvestrant in patients with...
Multigene Signature Can Help Tailor Chemo for Operable Triple-Negative Breast Cancer
WEDNESDAY, Oct. 30, 2024 -- For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, according to a study published...
American College of Surgeons, Oct. 19-22
The annual meeting of the American College of Surgeons was held this year from Oct. 19 to 22 in San Francisco and attracted participants from around the world, including...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.